Background
Objectives
Study Design
Results
Conclusions
Key words
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of Obstetrics & GynecologyReferences
- Minimally invasive surgery: national trends in adoption and future directions for hospital strategy.Surg Endosc. 2013; 27: 2253-2257
- Practice Bulletin No. 149: Endometrial cancer.Obstet Gynecol. 2015; 125: 1006-1026
U.S. Food and Drug Administration. FDA updated assessment of the use of laparoscopic power morcellators to treat uterine fibroids. December 2017. Silver Spring, MD. Available at: https://www.fda.gov/downloads/MedicalDevices/ProductsandMedicalProcedures/SurgeryandLifeSupport/UCM584539.pdf. Accessed August 14, 2018.
- Management of uterine fibroids. Comparative Effectiveness Review No. 195. (Prepared by the Vanderbilt Evidence-based Practice Center under Contract No. 290-2015-00003-I.) AHRQ Publication No. 17(18)-EHC028-EF.Agency for Healthcare Research and Quality, Rockville, MDDecember 2017 (Available at:)https://effectivehealthcare.ahrq.gov/topics/uterine-fibroids/research-2017Date accessed: November 1, 2018
- Incidence of unanticipated uterine pathology at the time of minimally invasive abdominal sacrocolpopexy.J Minim Invasive Gynecol. 2014; 21: 97-100
- Safety of manual morcellation after vaginal or laparoscopic-assisted vaginal hysterectomy.J Minim Invasive Gynecol. 2016; 23: 542-547
- Incidental gynecologic neoplasms in morcellated uterine specimens: a case series with follow-up.Hum Pathol. 2014; 45: 2311-2317
- Unanticipated uterine pathologic finding after morcellation during robotic-assisted supracervical hysterectomy and cervicosacropexy for uterine prolapse.Female Pelvic Med Reconstr Surg. 2014; 20: 113-115
- Incidence of occult leiomyosarcoma in presumed morcellation cases: a database study.Eur J Obstet Gynecol Reprod Biol. 2016; 197: 31-35
- Uterine pathology in women undergoing minimally invasive hysterectomy using morcellation.JAMA. 2014; 312: 1253-1255
- Cancer of the corpus uteri.in: Ries L.A.G. Young J.L. Keel G.E. Eisner M.P. Lin Y.D. Horner M.-J. SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. National Cancer Institute SEER Program, Bethesda, MD2007 (NIH Pub. No. 07-6215. Available at:)https://seer.cancer.gov/archive/publications/survival/Date accessed: September 27, 2018
- Statewide Planning and Research Cooperative System (SPARCS).(Available at:)https://www.health.ny.gov/statistics/sparcs/Date accessed: August 14, 2018
- NYS Cancer Registry and Cancer Statistics.(Available at:)https://www.health.ny.gov/statistics/cancer/registry/Date accessed: August 14, 2018
- Surveillance, Epidemiology, and End Results (SEER) Program. Site Recode ICD-O-3/WHO 2008 Definition.(Available at:)https://seer.cancer.gov/siterecode/icdo3_dwhoheme/index.htmlDate accessed: August 14, 2018
- Incidence and survival trends of uncommon corpus uteri malignancies in the Netherlands, 1989-2008.Int J Gynecol Cancer. 2012; 22: 599-606
American Joint Committee on Cancer. Collaborative Stage Data Collection System. Schema Version 02.05. Chicago, IL. Available at: http://cancerstaging.org/cstage/schema/Pages/version0205.aspx. Accessed August 5, 2018.
- In search of the perfect comorbidity measure for use with administrative claims data: does it exist?.Med Care. 2006; 44: 745-753
- Comorbidity measures for use with administrative data.Med Care. 1998; 36: 8-27
- A modified poisson regression approach to prospective studies with binary data.Am J Epidemiol. 2004; 159: 702-706
- The inconsistency of “optimal” cutpoints obtained using two criteria based on the receiver operating characteristic curve.Am J Epidemiol. 2006; 163: 670-675
- Sensitivity x PPV is a recognized test called the clinical utility index (CUI+).Eur J Epidemiol. 2011; 26: 251-252
U.S. Food and Drug Administration. Quantitative assessment of the prevalence of unsuspected uterine sarcoma in women undergoing treatment of uterine fibroids: summary and key findings. April 17, 2014. Silver Spring, MD. Available at: https://www.fda.gov/downloads/medicaldevices/safety/alertsandnotices/ucm393589.pdf. Accessed August 26, 2018.
- Risk of undetected cancer at the time of laparoscopic supracervical hysterectomy and laparoscopic myomectomy: implications for the use of power morcellation.Womens Health Issues. 2016; 26: 21-26
- Occult gynecologic cancer in women undergoing hysterectomy or myomectomy for benign indications.Obstet Gynecol. 2018; 131: 642-651
- Letter: Occult gynecologic cancer in women undergoing hysterectomy or myomectomy for benign indications.Obstet Gynecol. 2018; 132: 519
- The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis.Cancer. 2000; 89: 1765-1772
- Unexpected gynecologic malignancy diagnosed after hysterectomy performed for benign indications.Obstet Gynecol. 2015; 125: 397-405
- The prevalence of occult leiomyosarcoma at surgery for presumed uterine fibroids: a meta-analysis.Gynecol Surg. 2015; 12: 165-177
- The sensitivity of Medicare claims data for case ascertainment of six common cancers.Med Care. 1999; 37: 436-444
- Identifying diabetics in Medicare claims and survey data: implications for health services research.BMC Health Serv Res. 2014; 14: 150
Article info
Publication history
Footnotes
This project was supported by grant number R01HS024702 from the Agency for Healthcare Research and Quality. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality. The New York State Cancer Registry was supported in part by the Centers for Disease Control and Prevention’s National Program of Cancer Registries through cooperative agreement 5NU58DP006309 awarded to the New York State Department of Health. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
This project was mostly completed while Dr Desai was a full-time faculty member at Yale University. Dr Desai is currently an employee of CooperSurgical Inc with an adjunct appointment with Yale University. Dr Gross has received research funding from 21st Century Oncology and Pfizer, as well as funding to support new models of sharing clinical trial data from Johnson & Johnson and travel funding from Flatiron, Inc. Dr Wright has served as a consultant for Tesaro and Clovis Oncology. The other authors had no conflict of interest to declare.
Cite this article as: Desai VB, Wright JD, Gross CP, et al. Prevalence, characteristics, and risk factors of occult uterine cancer in presumed benign hysterectomy. Am J Obstet Gynecol 2019;221:39.e1-14.
